Sep. 3 at 6:31 AM
$ASND $NVO $RANI
Rani Therapeutics (NASDAQ: RANI) has positioned itself for massive market capture by appointing industry veteran Jesper Høiland as Head of Strategy.
Leveraging over 30 years of expertise from Novo Nordisk and Ascendis Pharma, Høiland is pivoting Rani into the lucrative multi-billion-dollar obesity sector via its disruptive RaniPill® platform.
The commercial thesis is rapidly validating. In July 2026, Rani announced breakthrough Phase 1 data for its weight-loss asset, RT-114, demonstrating an unprecedented bioavailability exceeding 150% compared to standard subcutaneous injections.
Backed by Høiland’s elite network, Rani has secured high-value R&D partnerships with ProGen and PegBio.
By successfully transforming painful GLP-1 injections into an oral blockbuster, Rani represents a highly lucrative, de-risked biotech growth opportunity.
